exidavnemab vs Prasinezumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline

exidavnemab

Developed by BioArctic AB and partners

Phase 2 in Parkinson's Diseasemonoclonal antibody
Weak signal

NCT06671938 · Phase 2 · completed

This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events (AEs) and serious adverse events (SAEs).". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Prasinezumab

Developed by Roche under a licence from Prothena Biosciences Limited

Phase 3 in Parkinson's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2029 · NCT07174310 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointexidavnemabPrasinezumab
OFF time, change—Not reported—Trial running · NCT07174310
ON time without troublesome dyskinesia, change—Not reported—Trial running · NCT07174310
UPDRS Part III, change—Not reported—Trial running · NCT07174310
MDS-UPDRS Part II, change—Not reported—Trial running · NCT07174310

OFF time, change

exidavnemab
—Not reported
Prasinezumab
—Trial running · NCT07174310

ON time without troublesome dyskinesia, change

exidavnemab
—Not reported
Prasinezumab
—Trial running · NCT07174310

UPDRS Part III, change

exidavnemab
—Not reported
Prasinezumab
—Trial running · NCT07174310

MDS-UPDRS Part II, change

exidavnemab
—Not reported
Prasinezumab
—Trial running · NCT07174310
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

exidavnemab: no structured comparison results are available for Parkinson's Disease.

Prasinezumab: registry results are on file for Parkinson's Disease, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · Prasinezumab's landscape